The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesELISA: Use at an assay dependent dilution.
IHC-P: Use at a concentration of 20 µg/ml. Requires periodate-lysine-paraformaldehyde fixative for 18-24 hrs. at 4°C.
WB: Use at a concentration of 8 - 20 µg/ml. Predicted molecular weight: 66 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionSeems to specifically activate progelatinase A. May thus trigger invasion by tumor cells by activating progelatinase A on the tumor cell surface. May be involved in actin cytoskeleton reorganization by cleaving PTK7.
Tissue specificityExpressed in stromal cells of colon, breast, and head and neck. Expressed in lung tumors.
Sequence similaritiesBelongs to the peptidase M10A family. Contains 4 hemopexin-like domains.
DomainThe conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
Post-translational modificationsThe precursor is cleaved by a furin endopeptidase.
Cellular localizationMembrane. Melanosome. Identified by mass spectrometry in melanosome fractions from stage I to stage IV.